Skip to main content Skip to navigation

Dr Mike Khan

Job Title
Senior Lecturer (Clinical)
Life Sciences
Research Interests

RNAi Tissue plasticity Cancer Biology Lipid metabolism Diabetes Head of Molecular Medicine @ Warwick and Director of Postgraduate Course in Cardiovascular risk and Organiser of MSc modules in CV risk


Executive Director Silence Therapeutics PLC 2013-present, CMO from 2012-2014, Head of Translational Medicine 2015-present: 3 years of board-level experience in Industry. Head hunted to join this RNAi therapeutics company, initially as an NED and advisor in 2012 and invited to become CMO and Executive Director later that year. Formulated company strategy for R and D, planning and initiating preclinical and translational projects. Managing relationships with CROs and academic collaborators. Active across many thematic areas of drug development from preclinical through regulatory and planning, initiation and running of Clinical Trials. Contributed to three successful fund-raising efforts and took part in all road-shows/funder presentations, raising over £80,000,000 since 2013. Invited speaker at several industry events/conferences. Have been the public face of the company at conferences. Over 30 years of clinical experience, including 17 years as a senior NHS consultant physician and clinical academic, in general medicine, diabetes and endocrinology: Run county coronary prevention and diabetes clinical services. General medical take and in-patient care. Strong track record in service development, research and high-level senior management both in the NHS and University. Have held numerous senior roles at national and international level, including with the EC and NICE. Much of this past expertise and experience is directly relevant to translational research, decision making and strategic planning in industry. Given, the emphasis on partnerships between academia and industry now in drug development, my experience of both sectors at high-level will be very useful. Maintained Clinical and research position at 1 day a week. This was deemed to be advantageous for Silence Therapeutics PLC and was accepted by UHCW and University of Warwick for the same reasons, namely helping to build academic-private sector partnerships. Has facilitated development of new clinical trials in HNSCC, a preclinical programme in preeclampsia and a drug delivery programme for ODN using conjugation chemistry. Other Relevant experience Expert advisor to NICE. Expert advisor and panel member Clinical Guidelines Development Group (CGDG) and NICE for Cardiovascular risk and lipid-lowering drugs 2012-2014. Made a substantial contribution, over 2 years, to developing and writing the new NICE guideline (CG181) on Lipid-lowering drugs and assessment of cardiovascular risk. Overall extended access to statins to over 5 million more adults in England by reducing the risk threshold for intervention from 20% to a 10% predicted risk of CVD over 10 years. Highly cited researcher, over 100 publications across basic science and clinical medicine including in Cell, Nature, BMJ and Lancet. Just under 3000 citations, H-factor 18. Published the second edition of the popular Molecular Biology of Cancer- Willey-Blackwell. Grants and awards, 2 active grants and over 2 million pounds funding from BBSRC and QNRF, looking at pregnancy-associated diabetes and colon cancer biomarkers respectively. Elected to FRCS and Association of Physicians. EC advisor. 2002- present. Senior administrative roles. Head of Molecular Medicine at University of Warwick from 2002-2006 (completed 5 year period). Member of Senior Management group for Department of Biological Sciences, 2002-2006. One of the pioneers of Warwick Systems Biology. Chair of the exam boards for Cardiovascular risk and Cancer biology MSc courses and Postgraduate awards. 2010- 2015: Member of the trust resuscitation committee and am senior member on the local ethics committee. Founder member and board for MLSRF charity (Chair- Sir Paul Nurse). Founder member and advisory board for the Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM). In 2011 and 2014, Organiser, scientific committee member and local host for HEART UK. Grant reviewer and research analyst Extensive experience reviewing large multi-million euro grants for the EC; Marie Curie, ITNs, STREPS, NoEs, IPs, from FP5 through to Horizon 2020. Also for the BBSRC, EPSRC and MRC in the UK. Also grants aimed specifically at private sector funding, including Eurostars. Experience in applying for Innovate UK grants. Acted as advisor on infrastructure funding to the Government of Cyprus on behalf of the EC. Frequent reviewer for scientific journals.

Title Funder Award start Award end
Taiwan Partnering Award for the Analysis of Digitised Images of Immunohistochemically (IHC) Stained Serial Tissue Sections of Mouse Pancreata BBSRC 01 May 2016 30 Apr 2018
Origin of new beta cells during pregnancy using PCLT and TIS microscopy BBSRC 01 May 2013 31 Oct 2017
Novel Biomarkers for early diagnosis and screening of colorectal cancer via computerized analysis of highly muliplexed protein fluorescence inmage data generated by novel toponome imaging system Qatar National Research Fund 01 Oct 2012 30 Sep 2015
Support for Dr M Khan - (Backdated 01/04/2005) University Hospitals Coventry and Warwickshire NHS Trust 01 Apr 2005 31 Mar 2013
Multichannel Microscopy, Applied to 1) Colon Cancer 2) Beta Cell Regeneration Royal Society 16 Mar 2011 15 Mar 2013
The Role of Adipose Tissue in Obesity: Beta Cell Crosstalk (ADIBET). European Commission 01 Jun 2008 31 May 2012
WPH Charitable Trust Foundation via MRF WPH Charitable Trust 01 Jan 2010 31 Dec 2010
Funding to support Sylvie Abouna (3) - five month extension (clinical trials account UHCW - T8922) University Hospitals Coventry and Warwickshire NHS Trust 01 May 2010 30 Sep 2010
Funding to support Sylvie Abouna (2) - one month extension (clinical trials account UHCW-T8922) University Hospitals Coventry and Warwickshire NHS Trust 01 Apr 2010 30 Apr 2010
Funding to Support Sylvie Abouna in Research Group University Hospitals Coventry and Warwickshire NHS Trust 01 Sep 2009 28 Feb 2010
Training Fellowship for Mr Luxian Zhou Medical Research Fund of Warwick 01 Oct 2007 30 Sep 2009
Transgenic modelling of beta-cell homeostasis EPSRC 01 Sep 2007 31 Aug 2009
Proof concept study for use of topical oral cyclo-oxygenase inhibitors (cox-1) mouthwash. Cancer Research UK 01 Apr 2007 31 Mar 2009
Use of unique animal models to study the reversible effects of hyperglycaemia on the arterial endothelium in vivo Wellcome Trust 01 Sep 2005 31 Aug 2008
Prevention of Beta Cell Apoptosis and Dysfunction by Exenatide in Endoenous and Transplanted Islets in Mouse Diabetes Models in Vivo Eli Lilly and Co Limited 01 Oct 2005 30 Sep 2007
Admin Support - Understanding the spread of cancer (metastasis) WPH Charitable Trust 01 Oct 2004 30 Sep 2007
Donation: Support for L Cheung - Cross reference with 11841 Sir Samuel Scott of Yews Trust 01 Oct 2004 01 Oct 2005
Donation: Support for L Cheung - cross ref with 11842 General Charities (Coventry) 01 Oct 2004 01 Oct 2005
Use of animal models to study regeneration of pancreatic islets in the adult Leverhulme Trust 01 Dec 2004 31 May 2005
Funding of Dr Mike Khan - Senior Clinical Lecturer University Hospitals Coventry and Warwickshire NHS Trust 01 Apr 2004 31 Mar 2005
Unrestricted Gift Pfizer Limited 01 Apr 2003 31 Mar 2004